Back to Search Start Over

Inhibition of lung microbiota-derived proapoptotic peptides ameliorates acute exacerbation of pulmonary fibrosis.

Authors :
D'Alessandro-Gabazza CN
Yasuma T
Kobayashi T
Toda M
Abdel-Hamid AM
Fujimoto H
Hataji O
Nakahara H
Takeshita A
Nishihama K
Okano T
Saiki H
Okano Y
Tomaru A
Fridman D'Alessandro V
Shiraishi M
Mizoguchi A
Ono R
Ohtsuka J
Fukumura M
Nosaka T
Mi X
Shukla D
Kataoka K
Kondoh Y
Hirose M
Arai T
Inoue Y
Yano Y
Mackie RI
Cann I
Gabazza EC
Source :
Nature communications [Nat Commun] 2022 Mar 23; Vol. 13 (1), pp. 1558. Date of Electronic Publication: 2022 Mar 23.
Publication Year :
2022

Abstract

Idiopathic pulmonary fibrosis is an incurable disease of unknown etiology. Acute exacerbation of idiopathic pulmonary fibrosis is associated with high mortality. Excessive apoptosis of lung epithelial cells occurs in pulmonary fibrosis acute exacerbation. We recently identified corisin, a proapoptotic peptide that triggers acute exacerbation of pulmonary fibrosis. Here, we provide insights into the mechanism underlying the processing and release of corisin. Furthermore, we demonstrate that an anticorisin monoclonal antibody ameliorates lung fibrosis by significantly inhibiting acute exacerbation in the human transforming growth factorβ1 model and acute lung injury in the bleomycin model. By investigating the impact of the anticorisin monoclonal antibody in a general model of acute lung injury, we further unravel the potential of corisin to impact such diseases. These results underscore the role of corisin in the pathogenesis of acute exacerbation of pulmonary fibrosis and acute lung injury and provide a novel approach to treating this incurable disease.<br /> (© 2022. The Author(s).)

Details

Language :
English
ISSN :
2041-1723
Volume :
13
Issue :
1
Database :
MEDLINE
Journal :
Nature communications
Publication Type :
Academic Journal
Accession number :
35322016
Full Text :
https://doi.org/10.1038/s41467-022-29064-3